|Dr. Jennifer K. Simpson||Pres, CEO & Director||541.59k||N/A||1968|
|Ms. Barbra C. Keck M.B.A., MBA||CFO & Sec.||374k||N/A||1978|
|Mr. John Purpura M.S.||Exec. VP & Global Head of Operations||385k||N/A||1961|
|Mr. Thomas Johnson||Sr. Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Robin Wagge||Sr. VP of Rubenstein Associates||N/A||N/A||N/A|
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.